cuts (Page 2)

Andrii Dodonov Update 2.00PM EST: Adds latest share move and Oppenheimer’s downgrade Cell therapy developer Cartesian Therapeutics (NASDAQ:RNAC) announced Tuesday that its lead asset, Descartes-08, reached the main goal in a mid-stage trial against the muscle disorder myasthenia gravis (MG). In conjunction with the data, the Gaithersburg, Maryland-based biotech announcedContinue Reading

Pgiam/iStock via Getty Images Shares of Incyte (NASDAQ:INCY) traded lower on Tuesday after BMO Capital Markets downgraded the drugmaker to underperform from market perform, citing the potential consequences of the company’s recently announced $2B share buybacks. The transaction targeted for up to $1.672B worth of Incyte’s (INCY) common stock “appearsContinue Reading